药石科技(300725) - 2024 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2024 was ¥383,025,884.53, a decrease of 14.39% compared to the same period last year[1] - Net profit attributable to shareholders for Q3 2024 was ¥33,099,319.24, down 17.57% year-on-year[1] - The net profit excluding non-recurring gains and losses for Q3 2024 was ¥20,117,133.75, a significant decline of 58.16% compared to the previous year[1] - The basic earnings per share for Q3 2024 was ¥0.1664, down 17.26% year-on-year[1] - The net profit for Q3 2024 was CNY 131,790,818.60, a decrease of 14.4% compared to CNY 154,046,255.25 in Q3 2023[14] - Operating profit for Q3 2024 was CNY 137,531,895.14, slightly down from CNY 137,936,719.39 in the same period last year[14] - The total comprehensive income for Q3 2024 was CNY 130,726,069.30, down from CNY 156,901,390.33 in Q3 2023, representing a decline of 16.7%[14] - Basic earnings per share for Q3 2024 were CNY 0.6626, compared to CNY 0.7715 in the same quarter last year, a decrease of 14.1%[14] Assets and Liabilities - Total assets at the end of Q3 2024 amounted to ¥4,915,519,528.69, reflecting a decrease of 3.69% from the end of the previous year[1] - The company's total assets decreased to approximately 4.916 billion CNY from 5.104 billion CNY at the beginning of the period[12] - The total liabilities decreased to approximately 2.015 billion CNY from 2.272 billion CNY at the beginning of the period[12] Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥188,877,638.63, an increase of 27.13% compared to the same period last year[1] - The net cash flow from operating activities was 189 million CNY, an increase of 27.13% year-on-year[9] - Cash recovered from investments rose by 79.48%, reaching ¥2,734,421,639.56, attributed to an increase in redeemed financial products[5] - Cash received from investment income increased by 53.11%, totaling ¥32,015,910.36, reflecting higher returns from financial investments[5] - Cash flow from operating activities netted CNY 188,877,638.63, up from CNY 148,570,068.07 in the previous year, indicating a 27% increase[17] - Cash flow from investment activities showed a net outflow of CNY 5,986,725.75, an improvement from a net outflow of CNY 453,085,157.78 in Q3 2023[18] - Cash flow from financing activities resulted in a net outflow of CNY 377,079,879.92, compared to a net inflow of CNY 206,338,439.86 in the same quarter last year[18] Revenue Breakdown - For the first three quarters of 2024, total revenue reached 1.128 billion CNY, down 12.67% year-on-year[9] - Revenue from drug research stage products and services was 253 million CNY, a slight decrease of 0.97% year-on-year, while revenue from drug development and commercialization stage products and services was 874 million CNY, down 15.58% year-on-year[9] - Domestic revenue was 326 million CNY, down 22.67% year-on-year, while international revenue was 802 million CNY, down 7.85% year-on-year[9] - Total revenue from operating activities increased to CNY 1,278,208,259.42, compared to CNY 1,258,185,266.27 in Q3 2023, reflecting a growth of 1.6%[17] Shareholder Information - The total number of common shareholders at the end of the reporting period was 32,367[6] - The largest shareholder, Yang Minmin, holds 20.74% of the shares, totaling 41,403,319 shares, with 12,500,000 shares pledged[6] Expenses and Investments - Research and development expenses for the year-to-date were ¥88,967,345.69, a decrease of 32.87% compared to the previous year[4] - Tax payments increased by 73.44%, amounting to ¥73,627,376.80, primarily due to higher income and value-added tax payments[5] - Cash paid for the acquisition of fixed assets decreased by 74.96%, amounting to ¥73,830,708.13, due to reduced construction investments[5] - Cash paid for investments increased by 57.79%, totaling ¥2,687,903,747.90, as the company purchased more financial products[5] - Cash paid for debt repayment surged by 98.58%, reaching ¥538,760,300.00, due to an increase in repaid bank loans[5] - Cash dividends and interest payments increased by 105.93%, totaling ¥76,714,938.48, reflecting higher cash dividend payments[5] Operational Efficiency - The company's gross profit margin declined, contributing to a decrease in net profit attributable to the parent company[9] - The company continues to optimize its R&D and production processes to enhance delivery efficiency and drive business growth[9] - The company has maintained stable expense ratios across various categories during the reporting period[9]